Cadrenal Therapeutics, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.5M
- Price
- $0.99
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.67%
- Volume
- 98.6K
About
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Quick stats
Shares outstanding3.6M
Computed float3.0M
Float / shares83.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001937993
Websitehttps://www.cadrenal.com
AI Summary
AI-generated1/16
minorneutralother
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
Cadrenal Therapeutics said CEO Quang X. Pham will give a webcast presentation and host virtual one-on-one meetings at the Lytham Partners Fall 2026 Investor Conference, held virtually on September 29-30, 2026.
The webcast is scheduled for 10:15 a.m. ET on Tuesday, September 29, with replay available afterward; investors can book 1x1 meetings through Lytham Partners.
The release recaps the pipeline without new data: CAD-1005 carries FDA Orphan Drug and Fast Track designations for heparin-induced thrombocytopenia, and the company recently submitted a Rare Pediatric Disease Designation request to the FDA for tecarfarin in Kawasaki disease.
This is routine investor-outreach content with no financial, clinical, or regulatory updates disclosed.